Ellen J. Kim, MD

Selected Publications

• Elghawy O, Yang AG, Sussman JH, Thomas CJ, Carter JS, Landsburg DJ, Svoboda J, Kim E, Rook AH, Chung J, Villasenor-Park J, Plastaras JP, LaRiviere M, Hubbeling H, Chelius M, Nasta SD, Chong EA, Schuster SJ, Barta SK. : Retrospective cohort study of novel oral agents lenalidomide and duvelisib for relapsed or refractory mycosis fungoides and Sézary syndrome. J Am Acad Dermatol. 92(3) : 634-636, Mar 2025
• Elghawy O, Yang AG, Sussman JH, Thomas CJ, Carter JS, Landsburg DJ, Svoboda J, Kim E, Rook AH, Chung J, Villasenor-Park J, Plastaras JP, LaRiviere M, Hubbeling H, Chelius M, Nasta SD, Chong EA, Schuster SJ, Barta SK. : Retrospective cohort study of novel oral agents lenalidomide and duvelisib for relapsed or refractory mycosis fungoides and Sézary syndrome. J Am Acad Dermatol Nov 2024 Notes: doi: 10.1016/j.jaad.2024.10.095.
• Villasenor-Park J, Chung J, Kim EJ : Cutaneous B-cell Lymphomas/Cutaneous Oncology Hematology Oncology Clinics 38(5) : 1111, October 2024
• Silva GS, Kim EJ, Barta SK, Chung J : Immune-related adverse events associated with mogamulizumab: a comprehensive review of the literature Expert Rev Anticancer Ther 24(9) : 819-827, Sep 2024 Notes: doi: 10.1080/14737140.2024.2379914.
• Asare C, Chen J, Ottevanger R, Scarisbrick J, Olsen EA, Tawa M, Thornton S, Kim E, Khan N, Larocca C, Shinohara MM. : Systematic literature review to identify patient-reported outcome measures for patients with cutaneous T-cell lymphoma. International Dermatology Outcomes Measures 11th Annual Meeting, Washington D.C. April 2024
• Rastogi S, Kim EJ, Gelfand JM, Loren AW, Baumrin E : Chronic graft-versus-host disease-associated muscle cramps: severity and response to immunomodulatory therapies Transplant Cell Ther 24 Jan 2024 Notes: doi: 10.1016/j.jtct.2023.12.674. Epub ahead of print.
• Weiner DW, Rastogi S, Lewis DJ, Cohen L, Choi S, Vittorio CC, Haun PL, Samimi SS, Villasenor-Park J, Bhansali RS, Chong EA, Landsburg DJ, Nasta SD, Schuster, Svoboda J, Kim EJ, Rook AH, Barta SK. : Mogamulizumab Multimodality Therapy with Systemic Retinoids, Interferon, or Extracorporeal Photopheresis for Advanced Cutaneous T-Cell Lymphoma Dermatologic Therapy Dec 2023 Notes: https://doi.org/10.1155/2023/7625926
• Bagot M, Kim YH, Geskin LJ, Ortiz-Romero P, Kim E, Mehta-Shah N, Dereure O, Oro S, Beylot-barry M, Dalle S, Jacobsen E, Lansigan F, Ram-Wolff C, Khodadoust MS, Battistella M, Gru A, Moins-Teisserenc H, Zinzani PL, Viott J, Paiva C, Muller M, Porcu P. : Lacutumab in Patients with Relapsed and Refractory Sezary Syndrome: Results from the Tellomak Phase 2 Trial American Society of Hematology Annual Meeting, San Diego, CA Dec 2023
• Polgione B, Alexander-Savino CV, Kim EJ, Mangold AR, Desimone J, Wong H, Rumage AT, Donini O, Haulenbeek A, Schaber CJ, Straube R, Pullion C, Rook AH. : HyBryte™ Use in Early-Stage Cutaneous T-cell Lymphoma Front Drug Discov 3 Nov 2023
• Gunter S and Kim EJ : Impact of Guidelines from the 2011 International Society for Cutaneous Lymphomas on Registered and Pivotal Clinical Trials in Cutaneous T-Cell Lymphoma: A Retrospective Cohort Study J Invest Dermatol 23 : 3038-5., Nov 2023 Notes: doi: 10.1016/j.jid.2023.10.011. Epub ahead of print.